Protagonist Therapeutics (PTGX) Stock Price, News & Analysis

Protagonist Therapeutics logo
$124.83 -6.12 (-4.67%)
Closing price 04:00 PM Eastern
Extended Trading
$124.50 -0.33 (-0.26%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Protagonist Therapeutics Stock (NASDAQ:PTGX)

Advanced

Key Stats

Today's Range
$124.00
▼
$131.28
50-Day Range
$128.75
▼
$148.18
52-Week Range
$77.00
▼
$160.81
Volume
565,199 shs
Average Volume
711,032 shs
Market Capitalization
$8.15 billion
P/E Ratio
26.45
Dividend Yield
N/A
Price Target
$166.67
Consensus Rating
Buy

Company Overview

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets.

The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Founded in 2006 and based in Newark, California, Protagonist is led by co-founder and Chief Executive Officer Dinesh V. Patel, Ph.D.

AI Generated. May Contain Errors.

Protagonist Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

PTGX MarketRank™: 
3.515697443365 of 5 stars

Protagonist Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 220th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Protagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 1 strong buy rating, 16 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Protagonist Therapeutics has a consensus price target of $166.67, representing about 33.5% upside from its current price of $124.83.

  • Amount of Analyst Coverage

    Protagonist Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Protagonist Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Protagonist Therapeutics are expected to decrease by -75.91% in the coming year, from $5.52 to $1.33 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Protagonist Therapeutics is 26.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.15.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Protagonist Therapeutics is 26.45, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.34.

  • Price to Book Value per Share Ratio

    Protagonist Therapeutics has a P/B Ratio of 12.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    16.69% of the float of Protagonist Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Protagonist Therapeutics has a short interest ratio ("days to cover") of 16.89, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Protagonist Therapeutics has recently decreased by 0.53%, indicating that investor sentiment is improving.
  • Dividend Yield

    Protagonist Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Protagonist Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Protagonist Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Protagonist Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,552,987.00 in company stock.

  • Percentage Held by Insiders

    5.19% of the stock of Protagonist Therapeutics is held by insiders.

  • Percentage Held by Institutions

    98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Protagonist Therapeutics' insider trading history.
Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PTGX Stock News Headlines

HC Wainwright Has Optimistic Opinion of PTGX FY2026 Earnings
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $221.00
See More Headlines

PTGX Stock Analysis - Frequently Asked Questions

Protagonist Therapeutics' stock was trading at $87.34 at the start of the year. Since then, PTGX stock has increased by 42.9% and is now trading at $124.83.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its earnings results on Thursday, November, 5th. The company reported $3.07 EPS for the quarter, beating the consensus estimate of $2.50 by $0.57. The company earned $274.41 million during the quarter, compared to analyst estimates of $238.49 million. Protagonist Therapeutics had a net margin of 62.04% and a trailing twelve-month return on equity of 42.83%.

Protagonist Therapeutics (PTGX) raised $90 million in an initial public offering (IPO) on Wednesday, August 10th 2016. The company issued 7,500,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

Top institutional investors of Protagonist Therapeutics include State Street Corp (5.33%), Voya Investment Management LLC (0.76%), Pictet Asset Management Holding SA (0.73%) and Stephens Investment Management Group LLC (0.72%). Insiders that own company stock include Dinesh V Ph D Patel, Suneel Gupta, Arturo Md Molina, Harold E Selick, Asif Ali, Bryan Giraudo, William D Waddill and Lewis T Williams.
View institutional ownership trends
.

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Palantir Technologies (PLTR), Block (XYZ), Tesla (TSLA) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
11/05/2026
Today
11/16/2026
Jefferies Global Healthcare Conference
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PTGX
CIK
1377121
Fax
N/A
Employees
141
Year Founded
2006

Price Target and Rating

High Price Target
$221.00
Low Price Target
$106.00
Potential Upside/Downside
+33.5%
Consensus Rating
Buy
Rating Score (0-4)
3.06
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
$4.72
Trailing P/E Ratio
26.45
Forward P/E Ratio
93.86
P/E Growth
N/A
Net Income
-$130.15 million
Net Margins
62.04%
Pretax Margin
63.49%
Return on Equity
42.83%
Return on Assets
40.29%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
19.85
Quick Ratio
19.85

Sales & Book Value

Annual Sales
$46.02 million
Price / Sales
177.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.83 per share
Price / Book
12.70

Miscellaneous

Outstanding Shares
65,270,000
Free Float
61,882,000
Market Cap
$8.15 billion
Optionable
Optionable
Beta
1.21

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:PTGX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners